Business Wire

Private Markets Firms Face Major Challenges in Opening and Maintaining Accounts

20.5.2025 10:00:00 CEST | Business Wire | Press Release

Share

A seemingly innocuous and run of the mill task, accounts and payments have become overly complicated, painful and time consuming for professionals operating in private markets. Today, Alpha Group International plc (LON:ALPH) is launching a new guide for fund managers and service providers. The guide offers advice and direction on the various aspects involved in setting up, managing and maintaining accounts, as well as how to ensure payments are made successfully.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250519149247/en/

A guide to accounts and payments for private markets

An uptick in regulations coupled with increasingly complex dynamics between investors, service providers and banks has complicated opening accounts and making payments. Private capital fund managers are now having to tackle nuanced and time-consuming onboardings with account providers, with each having their own unique process.

Delays in setting up the account can impact investor confidence; LPs might start to question a GP’s ability to execute on a deal. At best, the fund manager has to clarify AML and KYC information. At worst, it could mean their deal deadline is missed, which could mean returning capital to investors.

If GPs haven't considered and planned for this level of complexity, it’s possible (and from our experience highly likely) that the lack of transaction activity, coupled with the heightened AML and KYC requirements, will render their account commercially unviable for their banking provider. When that happens, GPs can quickly find themselves in a situation where their account is being closed at short notice.

This comprehensive guide details the various aspects involved in setting up, managing and maintaining accounts, as well as how to ensure payments are made successfully. Alpha also explores the potential risks, downfalls and solutions, including:

  • Key considerations on types of accounts and providers
  • Advice on account maintenance and management
  • Managing accounts across multiple jurisdictions
  • Exploring common challenges and what can go wrong
  • Being strategic when it comes to accounts and payments.

Alpha provides the world’s first purpose-built global accounts solution for the alternative investment industry. Fund managers and service providers can quickly and easily access local accounts across key investment jurisdictions and manage them all in one place, with the proactive support of a dedicated team who understands the industry. The company is listed on the FTSE 250 of the London Stock Exchange and supports close to 2,000 investment managers with a range of alternative banking solutions.

James Yates, Managing Partner and CFO at IK Partners said, “Having often experienced delays and uncertainty when trying to open bank accounts for investment entities, we decided to trial Alpha’s accounts solution. Since then, we have opened multiple accounts and each time have found the process to be fast, straightforward, and reliable. Their high levels of client service and ongoing support have been very refreshing – they are highly attentive, responsive and have a clear understanding of our industry and the pressures that come with it.”

Request a copy of the guide

To find out more about Alpha’s global accounts solution, visit www.alphagroup.com/accounts or contact info@alphagroup.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250519149247/en/

Contacts

info@alphagroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye